Teva Pays $54m To Settle Allegations Of Illegal Kickbacks
Alleged Violations Of The False Claims Act Involved Azilect And Copaxone
After attempting to dismiss a whistleblowers’ case, Teva has decided to pay a settlement of $54m to settle the allegations of illegal kickbacks and attempts to influence the prescription writing of neurologists with respect to the Israeli firm’s Azilect and Copaxone brands.
You may also be interested in...
Armas has kicked off 2020 with the launch of four generic injectables in the US.
While Sandoz looks for a new country head in Germany, Lupin has appointed a new chief corporate development officer and a Coherus executive has left the firm.
The Committee on Energy and Commerce of the US House of Representatives has requested a set of documents from the FDA in order to assess whether the agency is doing enough to address the challenge of approving complex generics within its existing authorities, or whether additional authority is needed.